Company intelligence / Profile preview
Apertor Pharmaceuticals
Alameda, California, United Statesapertorpharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Apertor has identified its first development candidate targeting the mTORC1/4E-BP1 complex for the treatment of solid tumors in Q1 2025, and is preparing for IND submission by December 2026.
- Therapeutic areas
- Oncology
- Modalities
- Molecular gluesHeterobifunctional drugsInterceptors
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Apertor Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apertor Pharmaceuticals.